Xeljanz: A new oral treatment for rheumatoid arthritis, now available on the PBS.
Xeljanz (Zel-jans) is a new oral treatment for adults with moderate to severe rheumatoid arthritis (RA). Now listed on the PBS, Xeljanz is available as an affordable alternative for patients who have found other RA treatments ineffective.
Xeljanz (tofacitinib citrate) belongs to a new class of medicines known as Janus kinase inhibitors. The medication works inside cells by blocking the signalling of proteins which cause inflammatory immune responses. This process has been proven to both relieve RA pain and prevent further damage to affected joints.
Taken twice daily, Xeljanz is an oral medication not an injection or infusion. The medication has been approved to be taken either separately or combination with other Disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate.
If you are one of the many Queenslanders who have been unsuccessful with your previous RA medications, ask your GP or rheumatologist about Xeljanz and how it may help you.
Xeljanz clinical trials and the listing on the PBS were featured recently on A Current Affair.